MedTrace Logo

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

NCT01298648 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1716

Last updated 2018-07-02

Study results available
· View outcomes & findings →

Summary

This study will be conducted to assess adverse drug reactions, incidence of adverse events, and factors that may affect the safety and effectiveness of Humira for the treatment of Crohn's disease.

Conditions

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Sadanori Abe · AbbVie

Eligibility

Min Age
16 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01298648 on ClinicalTrials.gov